【摘要】 目的 探討肺動脈高壓患者藥物靶向治療的效果與耐受性。 方法 回顧分析2008年1月〖CD3/5〗2009年8月期間8例肺動脈高壓患者分別接受波生坦及西地那非治療的臨床資料,評估其臨床表現、WHO肺動脈高壓功能分級、6 min步行距離及肺動脈收縮壓在基線及治療3個月后的變化。 結果 治療后3個月,患者均能耐受藥物治療,無嚴重不良反應發生。WHO肺動脈高壓功能分級在治療前平均(31±04),治療后為(23±09),明顯得到改善(P lt;005)。肺動脈收縮壓在治療前平均(695±112 ) mm Hg(1 mm Hg=0133 kPa),治療后為(483±124) mm Hg,明顯降低(P lt;005)。6 min步行距離在治療前平均(324±48) m,治療后為(400±43) m,明顯延長(P lt;005)。 結論 肺動脈高壓患者藥物靶向治療的療效顯著,且耐受良好。
【Abstract】 Objective To examine the effects of target medical therapy in patients with pulmonary arterial hypertension(PAH). Methods To determine the safety and efficacy of bosentan and sildenafil in eight patients with PAH.The patients’ clinical features, six minutes walking diastance, WHO functional class and systolic pulmonary arterial pressure (SPAP) were measured at baseline and at three months after initiating target medial treatment. Results At the three months followup assessments, WHO functional class was improved with 31±04 vs 23±09 (P lt;005); SPAP was significantly decreased with(695±112 ) mm Hg vs (483±124) mm Hg (P lt;005), the six minutes walking distance was significantly increased with(324±48) m vs(400±43) m (P lt;005). Target medical treatment was well tolerated. Conclusion Target medical treatment is well tolerated and has beneficial effects on PAH.

Citation： nts with Pulmonary Arterial HypertensionWTBXCUI Kaijun,FENG Yuan,JIANG Lingyun,XU Yuanning.. Clinical Study of Effects of Target Medical Therapy in Eight Patients with Pulmonary Arterial Hypertension. West China Medical Journal, 2010, 25(4): 662-. doi: Copy

Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved